Literature DB >> 12399440

Pituitary tumorigenesis in prolactin gene-disrupted mice.

Martha E Cruz-Soto1, Michael D Scheiber, Karen A Gregerson, Gregory P Boivin, Nelson D Horseman.   

Abstract

Targeted disruption [knockout (KO)] of the mouse prolactin (PRL) gene created an animal model of primary isolated PRL deficiency in which there is no detectable PRL bioactivity. Pituitary glands of young adult female PRLKO mice were hyperplastic, and many cells had expanded cytoplasms with granular accumulations of an N-terminal peptide encoded by the disrupted PRL gene (KO/10 peptide). Confocal imaging showed that the pituitaries in PRL(+/+) and PRL(+/-) females contained dense accumulations of apparently Golgi-associated immunoreactive PRL. PRLKO female mice (15-18 months old) developed hyperemic pituitary adenomas. The pituitary tumors in PRLKO mice synthesized the KO/10 peptide, which implies that the tumors arise from the lactotroph lineage. Anchorage-independent growth was observed among pituitary cells from PRLKO mice, aged 8 months or older, but not in cells from 3-month-old PRLKO mice. GH cells appeared to be normal in PRLKO pituitaries, but were displaced by the hyperplastic and hypertrophic growth of KO/10-positive cells. Bromocriptine suppressed mean pituitary weight in 8-month-old PRLKO mice compared with vehicle-treated PRLKO animals (20 +/- 0.01 and 60 +/- 10 mg; P < 0.01). We infer that pituitary lactotrophs of PRLKO mice suffer from a dual pathology that includes hypertrophy resulting from endoplasmic reticulum expansion and hyperplasia, with adenomatous transformation, in part as a consequence of disrupted dopaminergic feedback regulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399440     DOI: 10.1210/en.2002-220173

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

Review 1.  Collision lesions of the sella: co-existence of craniopharyngioma with gonadotroph adenoma and of Rathke's cleft cyst with corticotroph adenoma.

Authors:  N Karavitaki; B W Scheithauer; J Watt; O Ansorge; M Moschopoulos; A V Llaguno; J A H Wass
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 2.  Genesis of prolactinomas: studies using estrogen-treated animals.

Authors:  Dipak K Sarkar
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

3.  Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice.

Authors:  Hadley J Hartwell; Keiko Y Petrosky; James G Fox; Nelson D Horseman; Arlin B Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

4.  Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis.

Authors:  Vera Chesnokova; Kalman Kovacs; Anna-Valeria Castro; Svetlana Zonis; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2005-05-26

5.  mTOR promotes pituitary tumor development through activation of PTTG1.

Authors:  R Chen; J Duan; L Li; Q Ma; Q Sun; J Ma; C Li; X Zhou; H Chen; Y Jing; S Zhao; X Wu; H Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

Review 6.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 7.  The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.

Authors:  Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

8.  Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Authors:  Yunfei Wen; Behrouz Zand; Bulent Ozpolat; Miroslaw J Szczepanski; Chunhua Lu; Erkan Yuca; Amy R Carroll; Neslihan Alpay; Chandra Bartholomeusz; Ibrahim Tekedereli; Yu Kang; Rajesha Rupaimoole; Chad V Pecot; Heather J Dalton; Anadulce Hernandez; Anna Lokshin; Susan K Lutgendorf; Jinsong Liu; Walter N Hittelman; Wen Y Chen; Gabriel Lopez-Berestein; Marta Szajnik; Naoto T Ueno; Robert L Coleman; Anil K Sood
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

Review 9.  Potential of gene therapy for the treatment of pituitary tumors.

Authors:  R G Goya; D K Sarkar; O A Brown; C B Hereñú
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

10.  Prolactin and male fertility: the long and short feedback regulation.

Authors:  M K Gill-Sharma
Journal:  Int J Endocrinol       Date:  2009       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.